Kura Oncology, Inc.
NASDAQKURA reports on June 4 with short sellers at their most aggressive in months and the stock down 14% on the week — the question now is whether Komzifti's commercial numbers can shift that conviction. Short interest has pulled back slightly from the 22% level flagged in Tuesday's preview note, but remains heavy at roughly 18% of free float — still among the highest readings in…
Snapshot as of 3 Jun 2026
KURA reports on June 4 with short sellers at their most aggressive in months and the stock down 14% on the week — the question now is whether Komzifti's commercial numbers can shift that conviction. Short interest has…
KURA heads into its June 4 earnings report carrying one of the heaviest short positions in small-cap biotech — and the bears have been adding. Short interest has climbed to 22% of free float, up from roughly 20% six…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for KURA — free to start on ORTEX.
Sign up for free →Open KURA on ORTEX